Birgitta Grundmark's scientific contributions

Publication (1)

Full-text available
IntroductionThe safety profile of remdesivir, conditionally approved for COVID-19, was limited at its 2020 introduction. Adverse drug reactions (ADRs) for medicines are collected in VigiBase, the WHO Global Database of Individual Case Safety Reports (ICSRs).Objective This study aimed to provide a descriptive analysis of COVID-19 ICSR data focusing...


... 16 It is also possible that this real-world Veteran cohort had greater comorbidity than those enrolled in clinical trials. Remdesivir-associated liver injury has been observed in other real-world cohorts of critically ill patients with COVID-19 17 and pharmacovigilance studies 18,19 ; it has been associated with liver failure 20 and increased mortality. 21 Our study was not designed to analyze clinical outcomes of those observed to exhibit ALT elevations in the remdesivir-treated group. ...